Literature DB >> 34876828

Clinicopathological Characteristics Related to Etiologies of Erythema Nodosum: A 10-Year Retrospective Study.

Preeyachat Limtong1, Poonkiat Suchonwanit1, Kumutnart Chanprapaph1, Suthinee Rutnin1.   

Abstract

BACKGROUND: Erythema nodosum (EN) is the most common panniculitis associated with a wide variety of conditions. Updated studies regarding the clinicopathological manifestations related to etiologies of EN and its prognosis are limited.
OBJECTIVE: We aimed to explore the clinicopathological features in relation to the etiologies of EN and determine characteristics of disease recurrence and its predictive factors.
METHODS: A total of 169 patients with biopsy-proven EN or septal panniculitis from January 2008 to September 2018 were retrospectively reviewed. Patients were classified as either idiopathic or secondary EN. Patients' general information, clinical manifestations, investigations, and recurrence of EN were recorded. The details on histopathological findings were reviewed by a blinded dermatopathologist.
RESULTS: The mean age at diagnosis of EN was 40.6 ± 17.3 years. The majority of patients (85.2%) were female. Idiopathic EN was found in 62.7% of patients. Tuberculosis (23.8%) and drugs (23.8%) were the leading causes of secondary EN. In univariate logistic regression analysis, lesions on upper extremities (p = 0.018), fever (p = 0.003), clinical lymphadenopathy (p < 0.001) favored secondary EN. Histopathologically, the presence of focal peripheral lobular panniculitis with eosinophils was linked to idiopathic EN (p = 0.03). However, multivariable logistic regression analysis failed to demonstrate factors associated with secondary EN. Recurrence was found in 46.6% of patients with no identifiable predictive factors.
CONCLUSION: Although no clinical risk factors were associated with the etiology of EN, the histopathological presence of eosinophils in focal peripheral lobular panniculitis suggested idiopathic EN.
© 2021 Limtong et al.

Entities:  

Keywords:  leg nodules; panniculitis; septal panniculitis; subcutaneous mass; subcutaneous nodule

Year:  2021        PMID: 34876828      PMCID: PMC8643131          DOI: 10.2147/CCID.S343351

Source DB:  PubMed          Journal:  Clin Cosmet Investig Dermatol        ISSN: 1178-7015


Introduction

Erythema nodosum (EN) is the most common form of panniculitis characterized by symmetrical, erythematous, tender, warm nodules and plaques located on the pretibial areas.1 The incidence of EN is approximately one to five per 100,000 persons with a male-to-female ratio of 1:1 in children and 1:5 in adults.2,3 Although EN can occur in any age group, it is most frequently found in the second to fourth decades of life.4 EN is considered a hypersensitivity response to various antigens from a wide range of precipitating factors such as infection, inflammation, neoplasm, and drugs.1,3,5 Evidence of circulating immune complexes in early lesions supports the suggestion that the antigen, antibody, and complement play a significant role in the pathogenesis, and circulating immune complexes may contribute to tissue injury. However, some authors have reported a lack of circulating immune complexes in uncomplicated EN, and a type IV delayed hypersensitivity reaction has been proposed.3 EN can be classified according to the etiologies as primary or idiopathic EN and secondary EN when there is an identifiable cause.6 EN has also been defined histopathologically according to the chronology of lesions as acute and chronic EN.1,7,8 Approximately 32–72% of EN is idiopathic, while 28–68% is a secondary subtype.6,9–14 Conditions related to secondary EN remain inconclusive and vary according to triggering factors in the study period, ethnic, racial, and geographic differences.3,6,9–12 Regarding the clinical course, both idiopathic and secondary EN can resolve spontaneously within approximately 3–6 weeks without scarring.6,7 Few studies have shown that idiopathic EN tends to recur more frequently than secondary EN.6,9 Thus, identifying the link between clinical/histopathological parameters and the etiologies of EN to anticipate disease recurrence is important as it provides an accurate diagnosis and enables prompt management of the underlying diseases. However, there are limited studies regarding EN and its associated conditions.2,6,13,15–24 Moreover, studies in predictive factors link to the etiologies of EN are scarce.6,9,10,25 The primary objective of this study was to determine the clinicopathological features in relation to the etiologies of EN. Additionally, the recurrence rates and factors associated with disease recurrence were compared between primary and secondary EN.

Materials and Methods

Following the approval by the Mahidol University Review Board for Ethics in Human Research (MURA2018/885), we conducted a retrospective analytical study at the dermatology division, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand from January 2008 to September 2018. The study protocol was under the Principle of the Declaration of Helsinki. Patients diagnosed with EN based on compatible clinical manifestations and definite histopathology defined as septal panniculitis without vasculitis were included (Figure 1).1,7,26 The exclusion criteria were patients with incomplete medical and/or histopathological records, histopathological diagnoses of other types of panniculitis, and unavailable biopsy specimens for re-evaluation.
Figure 1

Histopathology of erythema nodosum; (A) Septal panniculitis without vasculitis (Hematoxylin-eosin stain, x40). (B) Higher magnification demonstrating septal fibrosis with lymphohistiocytic infiltration (Hematoxylin-eosin stain, x100).

Histopathology of erythema nodosum; (A) Septal panniculitis without vasculitis (Hematoxylin-eosin stain, x40). (B) Higher magnification demonstrating septal fibrosis with lymphohistiocytic infiltration (Hematoxylin-eosin stain, x100). Patients’ baseline characteristics (ie, age at diagnosis, gender, underlying diseases, history of prior/current medication), clinical data of EN (ie, onset, duration, symptoms, morphology, color, locations), extracutaneous manifestation (ie, fever, clinical lymphadenopathy), laboratory results, chest radiographic findings, and histopathological data were retrieved from the electronic medical record system and further analyzed. Recurrence of EN, defined as a reappearance of EN at least one month after the complete resolution, was also evaluated.6,9 Patients were further classified based on the etiologies as primary or idiopathic EN and secondary EN. Primary or idiopathic EN was defined by the absence of identifiable etiology that may lead to EN and secondary EN was diagnosed when there is an explicable cause contributing to the development of EN.6 Diagnoses of conditions and disorders leading to the development of secondary EN are as shown in Table 1.5,6,27–42
Table 1

Diagnostic Criteria for Diseases and Conditions Associated with Secondary Erythema Nodosum

DiseasesCriteria for Diagnosis
Mycobacterium tuberculosis (TB) infectionPresence of a positive culture result or a positive nucleic acid amplification test or acid-fast bacilli found in the specimen from the site of infection27
Latent tuberculosis infection (LTBI)Positive result of either the TST or IGRA without clinical symptoms of active TB infection27
Disseminated tuberculosis infectionPresence of evidence of hematogenous spreading of tubercle bacilli28
Nontuberculous mycobacteria (NTM) infectionConsistent of clinical status, radiologic result, and repeated isolation of NTM by positive culture or nucleic acid amplification test from clinical specimens (sputum, biopsy specimens, or blood)29,30
Streptococcal infectionPresence of the history of sore throat within the last 3 weeks with a positive throat swab culture or a positive rapid antigen detection test or high level of ASO6,41
Pseudomonas aeruginosa infectionConsidered as the cause of EN if concomitant presence of EN and positive hemoculture result and negative tissue culture result of the pathogen from the EN lesion5,31
Cytomegalovirus (CMV) infectionCMV as isolated or detected from the clinical specimen32
Human immunodeficiency virus (HIV) infectionPresence of demonstrable antibodies to HIV and/or HIV or one of its components was detected directly from blood specimen33
MumpsCompatible clinical symptoms together with positive serological result34
Disseminated candidiasisPresence of evidences demonstrating tissue invasion by Candida spp. from histological or culture results or repeated positive hemoculture results35
Behçet’s disease (BD)Present of symptoms as the 1990 ISG criteria for BD36 or the 2014 ICBD criteria for BD37
Hematologic malignanciesThe diagnoses of myeloid, lymphoid, and myeloproliferative neoplasms were based on WHO classification and cytogenetic abnormalities.38,39
SarcoidosisCompatible clinical features, radiological results and histopathological results of noncaseating granuloma in the absence of other alternative causes of the granuloma42
Drug-induced ENEstablished temporal correlation with the possible causative drugs, which contained the history of medication taken before the patient developed EN and improvement of lesions after ceasing the drug, in the absence of other precipitating causes40

Abbreviations: ASO, anti-streptolysin-O antibody; BD, Behçet’s disease; CMV, Cytomegalovirus; EN, erythema nodosum; HIV, human immunodeficiency virus; ICBD, International Criteria for Behçet’s disease; IGRA, interferon-gamma release assay; ISG, International Study Group; LTBI, latent Mycobacterium tuberculosis infection; NTM, Nontuberculous mycobacteria; TB, tuberculosis; TST, tuberculin skin test; WHO, World Health Organization.

Diagnostic Criteria for Diseases and Conditions Associated with Secondary Erythema Nodosum Abbreviations: ASO, anti-streptolysin-O antibody; BD, Behçet’s disease; CMV, Cytomegalovirus; EN, erythema nodosum; HIV, human immunodeficiency virus; ICBD, International Criteria for Behçet’s disease; IGRA, interferon-gamma release assay; ISG, International Study Group; LTBI, latent Mycobacterium tuberculosis infection; NTM, Nontuberculous mycobacteria; TB, tuberculosis; TST, tuberculin skin test; WHO, World Health Organization. All histopathological specimens were re-evaluated by a blinded dermatopathologist. The histopathological spectrum was chronologically classified as acute or chronic EN. Acute EN was identified when the sections revealed septal edema with hemorrhage and a prominent neutrophilic infiltration in the absence of septal fibrosis. Chronic EN was diagnosed when the histopathological sections demonstrated septal widening with fibrosis and a mixed inflammatory cellular infiltrate comprising mainly lymphocytes, histiocytes, and multinucleated giant cells.1,7,8 Additional histopathological assessments were performed from the epidermis down to subcutaneous tissue. The following features were evaluated ie, epidermal changes (normal, atrophy/thinning, hyperplasia); dermal changes (distribution and pattern of cell infiltrate, cytologic composition); inflammatory patterns of the subcutaneous tissue (septal panniculitis, lobular panniculitis, mixed septal and lobular panniculitis); subcutaneous cytologic composition (lymphocytes, neutrophils, eosinophils, plasma cells, histiocytes, granuloma, extravasated erythrocytes); vasculitis; and fat necrosis.

Statistical Analysis

Statistical analyses were performed using Stata Version 14.0 (StataCorp, College Station, TX). Categorical variables were expressed as a percentage, while continuous variables were demonstrated in mean ± SD for data with normal distribution and median (interquartile range, IQR) for data with non-normal distribution. According to the outcomes of our study (the etiology and recurrence of EN) which were both binary data, we utilized logistic regression analysis for evaluation of the association between each of the predictors composed of clinical manifestations, laboratory results, and histopathology. Except for clinical lymphadenopathy as a predictive factor, we applied exact logistic regression analysis due to the rarity of the variable. Multivariable logistic regression analysis was applied to the variables of which the p-value was less than 0.1. A p-value of less than 0.05 was considered statistically significant.

Results

Patients’ Characteristics

Of 264 biopsy-proven EN, 95 were excluded due to the absence of pathological slides for review (n=14) and incomplete medical records (n=81). One hundred and sixty-nine patients remained in the study for clinical and pathological re-evaluation (Figure 2).
Figure 2

Recruitment process and the study flow diagram.

Recruitment process and the study flow diagram. Demographic data, clinical features, and pathological results of EN are shown in Table 2. The mean age at diagnosis was 40.6 ± 17.3 years. One hundred and forty-four patients were female (85.2%), and 25 patients were male (14.8%). The female-to-male ratio was 5.8:1. The median time from the onset of the lesion to establishing the diagnosis of EN was 1 (0.3–3) month. The median follow-up duration was 2.3 (0.7–7.5) months. Most of the patients (75.7%) presented with tender erythematous subcutaneous nodules. The most frequent locations were the lower extremities (n=159, 94.6%), followed by the upper extremities (n=39, 23.2%), trunk (n=11, 6.5%), and face and neck region (n=6, 3.6%). Lesions that appeared on the bilateral shins were accounted for 68% of the patients. Concerning histopathology, the most common inflammatory cell infiltrates in the fibrous septum were lymphocytes (96.5%), histiocytes (66.9%), eosinophils (48.5%d and neutrophils (43.3%), respectively. Focal peripheral lobular panniculitis was noted in 37.9% of patients. There were no specific epidermal and dermal changes or evidence of fat necrosis on histopathology. Based on the histological spectrum, acute EN was found in 52 patients (30.8%), while chronic EN was documented in 117 patients (69.2%).
Table 2

Demographic Data, Clinicopathological Results of Erythema Nodosum

Characteristics(N = 169)
Demographic data
- Mean age at diagnosis (years [± SD])40.6 ± 17.3
- Sex; N (%)
 Male25 (14.8%)
 Female144 (85.2%)
- Median onset of EN (months [IQR])1 (0.3–3)
- Median follow-up duration (months [IQR])2.3 (0.7–7.5)
- Recurrence55/118 (46.6%)
- Median time of recurrence (months [IQR])3 (1–5.5)
Symptoms of EN; N (%)
- Asymptomatic17/165 (10.3%)
- Tenderness142/165 (86.1%)
- Pruritus2/165 (1.2%)
- Tenderness and pruritus4/165 (2.4%)
Morphology; N (%)
- Nodules128 (75.7%)
- Plaques52 (30.8%)
- Papules13 (7.7%)
- Patches7 (4.1%)
- Macules4 (2.4%)
- Cellulitis-like lesion1 (0.6%)
Color; N (%)
- Red134 (87.6%)
- Brown33 (21.6%)
- Purple9 (5.9%)
- Skin-color5 (3.3%)
- Gray2 (1.3%)
Location; N (%)
- Lower extremities159/168 (94.6%)
- Upper extremities39/168 (23.2%)
- Trunk11/168 (6.5%)
- Face and neck6/168 (3.6%)
Pathological result of EN; N (%)
- Acute EN52 (30.8%)
- Chronic EN117 (69.2%)

Abbreviations: EN, erythema nodosum; IQR, interquartile range; SD, standard deviation.

Demographic Data, Clinicopathological Results of Erythema Nodosum Abbreviations: EN, erythema nodosum; IQR, interquartile range; SD, standard deviation. Idiopathic EN was found in 106 patients (62.7%), while secondary EN was documented in 63 patients (37.3%) (Table 3). The most common identifiable etiologies for secondary EN were bacterial infections (n=24, 38.1%), drugs (n=15, 23.8%), and hematologic malignancies (n=9, 14.3%). Among the 24 patients with bacterial infections, Mycobacterium tuberculosis (TB) was the leading culprit organism (n=15, 62.5%) with TB lymphadenitis being the most common presentation (n=7, 46.7%), followed by pulmonary tuberculosis (n=5, 33.3%). Other causative bacterial infections included streptococcal infection (n=4, 16.7%), pseudomonas infection (n=4, 16.7%), and nontuberculous mycobacterium infection (n=1, 4.1%). Oral contraceptive was the most common culprit drug for EN (n=13, 86.7%). Another two patients with drug-induced EN were caused by granulocyte-colony stimulation factor (G-CSF) and vemurafenib. Among nine patients with EN related to hematologic malignancies, acute myeloid leukemia was the most frequent cause (n=4, 44.4%), followed by diffuse large B-cell lymphoma (n=3, 33.3%), chronic lymphocytic leukemia (n=1, 11.1%), and primary myelofibrosis (n=1, 11.1%).
Table 3

Etiologies of Erythema Nodosum

Characteristics(N = 169)
Idiopathic EN106 (62.7%)
Secondary EN63 (37.3%)
● Bacterial infections24 (38.1%)
 o Mycobacterium tuberculosis15 (62.5%)
  -TB lymphadenitis7 (46.7%)
  -Pulmonary TB5 (33.3%)
  -Latent TB infection2 (13.3%)
  -Disseminated TB1 (6.7%)
 o Streptococcal infection4 (16.7%)
 o Pseudomonas infection4 (16.7%)
 o Nontuberculous mycobacterium infection1 (4.1%)
● Viral infections
 o CMV3 (4.8%)
 o HIV1 (33.3%)
 o Mumps1 (33.3%)
● Fungal infection1 (33.3%)
 o Disseminated candidiasis1 (1.6%)
● Drugs15 (23.8%)
 o Oral contraceptive pills13 (86.7%)
 o Others (G-CSF, Vemurafenib)2 (13.3%)
● Hematologic malignancies9 (14.3%)
 o AML4 (44.4%)
 o DLBCL3 (33.3%)
 o CLL1 (11.1%)
 o Primary myelofibrosis1(11.1%)
● Behcet’s disease5 (7.9%)
● Pregnancy4 (6.3%)
● Lung cancer1 (1.6%)
● Sarcoidosis1 (1.6%)

Abbreviations: AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CMV, cytomegalovirus; DLBCL, diffuse large B-cell lymphoma; EN, erythema nodosum; G-CSF, granulocyte colony-stimulating factor; HIV, human immunodeficiency virus; IQR, interquartile range; SD, standard deviation; TB, tuberculosis.

Etiologies of Erythema Nodosum Abbreviations: AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CMV, cytomegalovirus; DLBCL, diffuse large B-cell lymphoma; EN, erythema nodosum; G-CSF, granulocyte colony-stimulating factor; HIV, human immunodeficiency virus; IQR, interquartile range; SD, standard deviation; TB, tuberculosis. With regard to EN management, all secondary EN patients were treated according to the identifiable cause, including cessation of the culprit drug. Treatment was prescribed in 99 of 106 patients (93.4%) and 44 of 63 patients (69.8%) diagnosed with idiopathic and secondary EN, respectively. The two most common oral medications for idiopathic and secondary EN were colchicine (83.8% VS 79.6%) and non-steroidal anti-inflammatory drugs (NSAIDs) (74.8% VS 70.5%) (Table 4). Oral potassium iodide was given in refractory cases of both groups (19.2% of idiopathic EN VS 22.7% of secondary EN). Intralesional corticosteroid injection was performed in one case of idiopathic EN. The median time of EN resolution after treatment was 5 (3–10) weeks and 4 (2–6) weeks for idiopathic and secondary EN, respectively.
Table 4

Treatment of Erythema Nodosum

CategoriesIdiopathic EN (N = 106)Secondary EN (N = 63)
Systemic treatment
- Yes99/106 (93.4%)Yes 44/63 (69.8%)
- No7/106 (6.6%)No 19/63 (30.2%)
Median duration to resolution (weeks [IQR])
- After initiation of treatment5 (3–10)4(2–6)
- Spontaneous resolution without treatment3.5 (1.5–4)4
Systemic medication
-Colchicine83/99 (83.8%)35/44 (79.6%)
-NSAIDs74/99 (74.8%)31/44 (70.5%)
 o Indomethacin69/74 (93.2%)24/31 (77.4%)
 o Naproxen4/74 (5.4%)6/31 (19.4%)
 o Diclofenac1/74 (1.4%)0/31 (0%)
 o Ibuprofen0/74 (0%)1/31 (3.2%)
-SSKI19/99 (19.2%)10/44 (22.7%)
-ASA3/99(3.0%)0/44 (0%)
-HCQ1/99 (1.0%)1/44 (2.3%)

Abbreviations: ASA, acetylsalicylic acid; EN, erythema nodosum; HCQ, hydroxychloroquine; IQR, interquartile range; NSAIDs, non-steroidal anti-inflammatory drugs; SD, standard deviation; SSKI, saturated solution of potassium iodide.

Treatment of Erythema Nodosum Abbreviations: ASA, acetylsalicylic acid; EN, erythema nodosum; HCQ, hydroxychloroquine; IQR, interquartile range; NSAIDs, non-steroidal anti-inflammatory drugs; SD, standard deviation; SSKI, saturated solution of potassium iodide. Focusing on secondary EN caused by TB infection, the median time from the onset of EN lesions to diagnoses of TB infection was 2.3 (1.3–4.3) months, and the median time of EN resolution after initiating anti-tuberculosis drugs was 3 (2–5) months. During the treatment, 5 of 15 patients (33.3%) found 1 episode of EN recurrence and none found recurrence after completion of the treatment.

Clinicopathological Manifestations Related to Etiologies of EN

Regarding univariate logistic regression analysis, the lesions located on the upper extremities (OR 2.42, 95% CI [1.17, 5.01], p = 0.018, Figure 3), fever (OR 3.33, 95% CI [1.52, 7.30], p = 0.003), and clinical lymphadenopathy (OR 20.8, 95% CI [3.12, ∞], p < 0.001) were associated with secondary EN. Histopathologically, the presence of focal peripheral lobular panniculitis also favored secondary EN (OR 1.93, 95% CI [1.01, 3.65], p = 0.045). In contrast, eosinophils in focal peripheral lobular panniculitis (Figure 4), found in 60.9%, was significantly related to idiopathic EN (OR 3.17, 95% CI [1.11, 9.04], p = 0.030). However, there was no statistically significant association between acute/chronic EN and the etiological subtype of EN (p = 0.578), and no independent risk factors for etiologies of EN were identified after applied to multivariable analysis (Table 5).
Figure 3

Erythema nodosum at the dorsum of the left hand in a patient diagnosed with acute myeloid leukemia.

Figure 4

Histopathology of primary erythema nodosum; (A) Septal panniculitis with focal peripheral lobular infiltration (Hematoxylin-eosin stain, x40). (B) Higher magnification demonstrating numerous eosinophils in the area of focal peripheral lobular panniculitis (Hematoxylin-eosin stain, x400).

Table 5

Clinicopathological Findings and Investigations in Relations to Secondary Erythema Nodosum

FactorsLogistic Regression Analysis
OR95% CIp-value
Clinical manifestations
- Presence of lesions on upper extremities2.42[1.17, 5.01]0.018*
- Fever3.33[1.52, 7.30]0.003*
- Cough7.12[0.78, 65.18]0.082
- Arthralgia2.28[0.89, 5.85]0.087
- Lymphadenopathy20.8[3.12, -]a<0.001*
Histopathological findings
- Presence of focal peripheral lobular panniculitis1.93[1.01, 3.65]0.045*
- Presence of focal peripheral lobular panniculitis with eosinophils0.32[0.11, 0.90]0.030*
- Chronic EN0.83[0.42, 1.62]0.578

Notes: *Statistically significant. aCannot demonstrate the upper value of 95% confidence interval from the exact logistic regression analysis due to the value of approaching infinity.

Abbreviations: CI, confidence interval; EN, erythema nodosum; OR, odds ratio.

Clinicopathological Findings and Investigations in Relations to Secondary Erythema Nodosum Notes: *Statistically significant. aCannot demonstrate the upper value of 95% confidence interval from the exact logistic regression analysis due to the value of approaching infinity. Abbreviations: CI, confidence interval; EN, erythema nodosum; OR, odds ratio. Erythema nodosum at the dorsum of the left hand in a patient diagnosed with acute myeloid leukemia. Histopathology of primary erythema nodosum; (A) Septal panniculitis with focal peripheral lobular infiltration (Hematoxylin-eosin stain, x40). (B) Higher magnification demonstrating numerous eosinophils in the area of focal peripheral lobular panniculitis (Hematoxylin-eosin stain, x400).

Factors Associated with Recurrence of EN

Of a total 118 follow-up patients, recurrence was noted in 55 patients (46.6%), being 51.4% (n=36) and 39.5% (n=19) of cases with idiopathic and secondary EN, respectively. The most common conditions of secondary EN related to the highest recurrence rates were found equally in TB infection and drugs (n=5, 26.3%). There were no associations between clinical manifestations, laboratory results, histopathology, etiological subtypes of EN (p = 0.206), and the disease recurrence.

Discussion

Our study showed a predominant proportion of idiopathic EN in study subjects (62.7%), which was comparable with previous studies (32–72%).6,10–12 For secondary EN, the most common causes demonstrated in our study were TB infection (23.8%) and drugs (23.8%). The etiology of EN is variable among the studies. Prior reports noted that streptococcal infection was the leading cause of EN, ranging from 11–44%.3,6,10,13,15,21 On the contrary, previous studies from Thailand dating approximately 20 years back revealed that the most prevalent etiology was TB infection (12%).11,12 As Thailand is an endemic area for TB, the primary cause of secondary EN in our study remained the same.43 Also, Bjorn-Mortensen et al have documented that the incidence of EN increases in the TB endemic regions.44 Regarding drug-induced EN, the most common causative agent from our data was oral contraceptive pills accounting for nearly 90% of drug-induced EN. This was in line with the literature.4,14,40,45 However, two patients from our study developed EN precipitated by other drugs. Intriguingly, one of which was vemurafenib, a BRAF inhibitor, used for the treatment of melanoma, also previously reported as a possible culprit for EN.46–49 Another patient developed EN precipitated by G-CSF, which has been documented in the literature as well.50,51 Treatment of EN should be directed to the underlying associated condition. The majority of the patients required only symptomatic treatments and bed rest.1,3,5 Compression bandages and limb elevation may be used for edema and pain relief. Aspirin and NSAIDs, such as indomethacin or naproxen, may be used for pain control. Colchicine has been recommended, particularly in EN patients with Behçet's disease. In refractory disease, oral potassium iodide may be prescribed.1,3 From our study, the two most common medications, including colchicine and NSAIDs, were prescribed in both idiopathic and secondary EN with good clinical response and tolerable side effects. Oral potassium iodide was given in the refractory cases, corresponding to the literature review.1,3 Other reported medications such as systemic and intralesional corticosteroids, dapsone, hydroxychloroquine, cyclosporin, and thalidomide have been used as a treatment option for EN.1,3,5 Univariate logistic regression analysis in our study showed that lesions on upper extremities were related to secondary EN (p = 0.018). Furthermore, the common etiologies of secondary EN presented on the upper extremities were hematologic malignancies (n=6, 28.6%) and Pseudomonas aeruginosa (P. aeruginosa) infection (n=4, 19.0%). In general, EN typically occurs on the shins and is rarely distributed in other parts of the body, namely the thighs, forearms, and trunk.52 However, data on non-pretibial EN linked to secondary causes are still inconclusive and evidence is mainly confined to case reports/series. A study by Dogan et al stated that non-pretibial locations were significantly associated with secondary EN (p = 0.02).25 Alvarez-Lario et al revealed that EN lesions on the forearm were related to sarcoidosis and tuberculosis.10,53 Wilk et al reported three patients with EN presenting on the upper extremities, two of which were diagnosed with idiopathic EN, while the other had upper respiratory tract infection.52 Another report by Jones et al demonstrated a case of EN with lesions on the upper extremities from post-streptococcal infection.54 Our study demonstrated that atypical locations of EN, particularly on the upper extremities may have an association with secondary causes. Future prospective studies are required for this presumptive association. Based on the clinical manifestations and investigations related to secondary EN, a study by Mert et al demonstrated that fever, leucocytosis, elevated C-reactive protein level, increased erythrocyte sedimentation rate, cough, sore throat, diarrhea, arthritis, and abnormal chest radiographic findings were significantly linked to secondary EN.6 These clinical features and laboratory findings related to secondary EN were due to post-streptococcal infection leading to acute rheumatic fever and its complications.6 The presence of fever from their study may be due to TB infection documented as one of the two most common causes of secondary EN.6 According to univariate analysis, our data revealed that fever (p = 0.003) and clinical lymphadenopathy (p < 0.001) were associated with secondary EN. TB infection was one of two main precipitating causes for secondary EN and was the most frequent etiology of secondary EN presenting with fever (n=4, 20.0%) or clinical lymphadenopathy (n=3, 37.5%) reported in our study. This study demonstrated that the presence of tissue eosinophils on the background of focal peripheral lobular panniculitis and septal panniculitis was significantly associated with idiopathic EN (p = 0.030). Early lesions of EN, eosinophils can be primarily found in the biopsy tissue.8,55 As the main etiologies of secondary EN in our study were bacterial infections (eg, TB, streptococcal, and P. aeruginosa infections) and inflammatory cells released to combat bacterial infection are usually neutrophils and lymphocytes rather than eosinophils, this may explain why eosinophils were less predominant on histopathological sections in cases with secondary EN.56–59 Our study showed that the histopathological classification of EN as acute or chronic was unrelated to the etiologies of EN. This result may be affected by both the duration of the lesion and the time of patient visit. As a component of inflammatory cell infiltrates varies with the age of lesions and the patient’s skin biopsies were possibly not performed at the time of maximal disease intensity, misclassification of acute and chronic EN may have occurred. However, our study demonstrated that neither the diagnosis of acute/chronic EN (p = 0.234) nor the etiologies classified as primary/secondary EN (p = 1.000) were linked to the duration from the disease onset to the time of skin biopsy. Therefore, our results suggested a weak role between the chronological classification of EN on histopathology and the etiology of EN. With regard to factors associated with EN recurrence, the study did not demonstrate significant links between clinical manifestations, laboratory results, etiology of EN, and disease recurrence. Unlike previous studies, this study’s recurrence rate of secondary EN (39.5%) was higher than previously reported (2.1–17.9%).6,9 We propose that the recurrence rate may depend on the chronicity of the underlying condition. Acute infectious processes such as poststreptococcal infection and other upper respiratory tract infections required a shorter treatment duration, resulting in a lower rate of EN recurrence.6,9 While chronic diseases, such as TB required a longer treatment period and may have led to higher recurrence. The present study is subjected to several limitations. It was analyzed retrospectively; selection and recall bias, as well as incompleteness of data, may have occurred. Besides, this was a single-center study carried out at our referral hospital. Therefore, mild cases may have been missed and patients may have had more severe underlying conditions.

Conclusion

Our study demonstrated that no significant associations between clinical manifestations and etiology of EN. However, histopathological features of focal peripheral lobular panniculitis with eosinophils in addition to the typical septal panniculitis favored idiopathic EN. Further prospective clinicopathological studies of EN from various geographical areas are recommended to validate the study outcome.
  50 in total

Review 1.  Overview of the immune response.

Authors:  David D Chaplin
Journal:  J Allergy Clin Immunol       Date:  2010-02       Impact factor: 10.793

Review 2.  An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.

Authors:  David E Griffith; Timothy Aksamit; Barbara A Brown-Elliott; Antonino Catanzaro; Charles Daley; Fred Gordin; Steven M Holland; Robert Horsburgh; Gwen Huitt; Michael F Iademarco; Michael Iseman; Kenneth Olivier; Stephen Ruoss; C Fordham von Reyn; Richard J Wallace; Kevin Winthrop
Journal:  Am J Respir Crit Care Med       Date:  2007-02-15       Impact factor: 21.405

Review 3.  Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease.

Authors: 
Journal:  Lancet       Date:  1990-05-05       Impact factor: 79.321

4.  Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanoma.

Authors:  Guy Ben-Betzalel; Erez N Baruch; Ben Boursi; Yael Steinberg-Silman; Nethanel Asher; Ronnie Shapira-Frommer; Jacob Schachter; Gal Markel
Journal:  Eur J Cancer       Date:  2018-08-07       Impact factor: 9.162

Review 5.  Erythema nodosum-like lesions during BRAF inhibitor therapy: Report on 16 new cases and review of the literature.

Authors:  R Mössner; L Zimmer; C Berking; C Hoeller; C Loquai; E Richtig; K C Kähler; J C Hassel; R Gutzmer; S Ugurel
Journal:  J Eur Acad Dermatol Venereol       Date:  2015-03-06       Impact factor: 6.166

6.  Erythema nodosum: etiologic and predictive factors in a defined population.

Authors:  C García-Porrúa; M A González-Gay; M Vázquez-Caruncho; L López-Lazaro; M Lueiro; M L Fernández; J Alvarez-Ferreira; R M Pujol
Journal:  Arthritis Rheum       Date:  2000-03

7.  Histopathologic spectrum of erythema nodosum.

Authors:  Stacy Thurber; Sabine Kohler
Journal:  J Cutan Pathol       Date:  2006-01       Impact factor: 1.587

8.  Erythema Nodosum, Early Stage-A Subcutaneous Variant of Leukocytoclastic Vasculitis? Clinicopathological Correlation in a Series of 13 Patients.

Authors:  Michael Wilk; Bettina G Zelger; Kinan Hayani; Bernhard Zelger
Journal:  Am J Dermatopathol       Date:  2020-05       Impact factor: 1.533

Review 9.  Eosinophils from Physiology to Disease: A Comprehensive Review.

Authors:  Giuseppe A Ramirez; Mona-Rita Yacoub; Marco Ripa; Daniele Mannina; Adriana Cariddi; Nicoletta Saporiti; Fabio Ciceri; Antonella Castagna; Giselda Colombo; Lorenzo Dagna
Journal:  Biomed Res Int       Date:  2018-01-28       Impact factor: 3.411

10.  Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America.

Authors:  Stanford T Shulman; Alan L Bisno; Herbert W Clegg; Michael A Gerber; Edward L Kaplan; Grace Lee; Judith M Martin; Chris Van Beneden
Journal:  Clin Infect Dis       Date:  2012-09-09       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.